Shot in the DYRK

Felicitex Therapeutics Inc. is discovering and developing small molecule cancer agents that target cell quiescence, a mechanism cancer cells can use to resist treatment.

Cell quiescence is a reversible phenomenon where cells stop dividing and enter a dormant state with greatly reduced nutrient and energy requirements. Though normal cells may become quiescent for various reasons, cancer cells can become quiescent for an indefinite amount of time to protect themselves from chemotherapies that target dividing cells or deprive them of nutrients or growth factors...